Charles Eby

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. doi request reprint Novel anticoagulants and laboratory testing
    C Eby
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Lab Hematol 35:262-8. 2013
  2. doi request reprint Warfarin pharmacogenetics: does more accurate dosing benefit patients?
    Charles Eby
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA
    Semin Thromb Hemost 38:661-6. 2012
  3. doi request reprint Antiphospholipid syndrome review
    Charles Eby
    Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, St Louis, MO 63110, USA
    Clin Lab Med 29:305-19. 2009
  4. doi request reprint Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias
    Charles Eby
    Department of Pathology and Immunology and Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Br J Haematol 145:151-63. 2009
  5. pmc Genetic-based dosing in orthopedic patients beginning warfarin therapy
    Eric A Millican
    Department of Medicine, Washington University in St Louis, MO 63110, USA
    Blood 110:1511-5. 2007
  6. pmc Gamma-glutamyl carboxylase and its influence on warfarin dose
    Cristi R King
    Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri 63110, USA
    Thromb Haemost 104:750-4. 2010
  7. doi request reprint Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose
    Cristi R King
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Clin Pathol 129:876-83. 2008
  8. ncbi request reprint Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
    Deepak Voora
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Haemost 93:700-5. 2005
  9. ncbi request reprint The pharmacogenetics of coumarin therapy
    Deepak Voora
    Washington University School of Medicine, Departments of Medicine and of Pathology, St Louis, MO 63110, USA
    Pharmacogenomics 6:503-13. 2005
  10. doi request reprint The occurrence of antibodies to heparin-platelet factor 4 in cardiac and thoracic surgical patients receiving desirudin or heparin for postoperative venous thrombosis prophylaxis
    Michael S Avidan
    Department of Anesthesiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Res 128:524-9. 2011

Collaborators

Detail Information

Publications16

  1. doi request reprint Novel anticoagulants and laboratory testing
    C Eby
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Lab Hematol 35:262-8. 2013
    ..This is a rapidly changing field, and coagulation laboratory experts have a major role in ensuring patients receive appropriate testing and accurate interpretations of results...
  2. doi request reprint Warfarin pharmacogenetics: does more accurate dosing benefit patients?
    Charles Eby
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA
    Semin Thromb Hemost 38:661-6. 2012
    ..Results from ongoing international randomized clinical trials should provide clarity about the place of warfarin pharmacogenetics in personalized medicine...
  3. doi request reprint Antiphospholipid syndrome review
    Charles Eby
    Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, St Louis, MO 63110, USA
    Clin Lab Med 29:305-19. 2009
    ....
  4. doi request reprint Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias
    Charles Eby
    Department of Pathology and Immunology and Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Br J Haematol 145:151-63. 2009
    ..Due to the infrequency of most of these haemostasis complications, available information is typically based on retrospective cases or series...
  5. pmc Genetic-based dosing in orthopedic patients beginning warfarin therapy
    Eric A Millican
    Department of Medicine, Washington University in St Louis, MO 63110, USA
    Blood 110:1511-5. 2007
    ..If validated, this model should provide a safer, more effective process for initiating warfarin therapy...
  6. pmc Gamma-glutamyl carboxylase and its influence on warfarin dose
    Cristi R King
    Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri 63110, USA
    Thromb Haemost 104:750-4. 2010
    ..Given the potentially low marginal cost of adding this SNP to existing genotyping platforms, we have modified our non-profit website (www.WarfarinDosing.org) to accommodate knowledge of this variant...
  7. doi request reprint Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose
    Cristi R King
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Clin Pathol 129:876-83. 2008
    ..Current commercial platforms provide accurate and rapid genotypes for pharmacogenetic dosing during initiation of warfarin therapy...
  8. ncbi request reprint Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
    Deepak Voora
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Haemost 93:700-5. 2005
    ..Prospective, perioperative pharmacogenetics-based dosing of warfarin is feasible; however, further evaluation in a randomized, controlled study is recommended...
  9. ncbi request reprint The pharmacogenetics of coumarin therapy
    Deepak Voora
    Washington University School of Medicine, Departments of Medicine and of Pathology, St Louis, MO 63110, USA
    Pharmacogenomics 6:503-13. 2005
    ..A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation...
  10. doi request reprint The occurrence of antibodies to heparin-platelet factor 4 in cardiac and thoracic surgical patients receiving desirudin or heparin for postoperative venous thrombosis prophylaxis
    Michael S Avidan
    Department of Anesthesiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Res 128:524-9. 2011
    ..This randomized, exploratory study compared the incidence of heparin-dependent antibodies associated with subcutaneous (SC) desirudin or heparin given for deep-vein thrombosis prophylaxis following cardiac and thoracic surgery...
  11. doi request reprint A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery
    George Despotis
    Departments of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Transfusion 48:2S-30S. 2008
  12. ncbi request reprint Use of pharmacogenetics to guide warfarin therapy
    Deepak Voora
    Departments of Medicine and Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Drugs Today (Barc) 40:247-57. 2004
    ..The genotype assays for genetic variants relevant to warfarin are widely used and are being developed for commercial use (5), making the promise of a pharmacogenetics-based approach a near reality...
  13. ncbi request reprint Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Brian F Gage
    Department of Medicine, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave St Louis, Missouri 63110, USA
    Thromb Haemost 91:87-94. 2004
    ..001). In conclusion, the maintenance warfarin dose can be estimated from demographic, clinical, and pharmacogenetic factors that can be obtained at the time of warfarin initiation...
  14. ncbi request reprint Transfusion medicine service policies for recombinant factor VIIa administration
    Lawrence Tim Goodnough
    Department of Medicine, Washington University School of Medicine Barnes Jewish Hospital, St Louis, Missouri, USA
    Transfusion 44:1325-31. 2004
    ..Currently, the decision on when and where to use rFVIIa for patients with uncontrolled bleeding continues to be one that must be made by individual physicians, assisted by their hospital pharmacotherapeutics and transfusion committees...
  15. doi request reprint Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients with HIT
    - Yi Qian
    Department of Pathology, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Appl Thromb Hemost 16:251-60. 2010
    ..Furthermore, the assays used in these studies would be valuable for HIT diagnosis, prevention, and treatment...
  16. ncbi request reprint Hemostatic complications associated with paraproteinemias
    Charles Eby
    Department of Pathology and Immunology and Medicine, Washington University School of Medicine, Box 8118, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Curr Hematol Rep 2:388-94. 2003
    ..Management of paraprotein-related hemostatic complications varies in strategy and efficacy, depending on the underlying mechanism and type of lymphoproliferative disease...